Johnson & Johnson (JNJ) Risk Factor Changes

To meet business objectives, the Company relies on both internal information technology (IT) systems and networks, and those of third parties and their vendors, to process and store sensitive data (including confident…

While certain of the announced tariffs have been delayed, the U.S.

Changes in tax laws or regulations in the U.S.

The Company is subject to an increasing number of costly and complex governmental regulations in the countries in which operations are conducted which may have a material adverse affect on the Company’s financial cond…

The threat of counterfeit medicines could adversely impact our business and reputation by impacting patient confidence in our authentic products, potentially resulting in lost sales, product recalls, and an increased…

controls, to address this risk.

The Company cannot predict the effect of the planned separation on the trading price of shares of its common stock, and market value of shares of its common stock may be less than, equal to or greater than the market…

Following the planned separation, the price of shares of the Company's common stock may fluctuate significantly

The Company will incur significant expenses in connection with the planned separation.

The costs to complete the planned separation will be significant.

In October 2025, the Company announced its intention to separate the Company's Orthopaedics business.

The planned separation of the Company's Orthopaedics business may not be completed on the terms or timeline currently contemplated, if at all, and may not achieve the expected results

Risks related to the planned separation of our Orthopaedics business